Depression and Cardiovascular Risk Markers: Effects of Rosuvastatin Therapy

University Hospital, Akershus

Overview

The purpose of this study is to investigate whether rosuvastatin decreases measures of inflammation in depressive patients.

Depression is associated with increased risk of cardiovascular disease, in which one possible mechanism is systemic inflammation. Further, patients at high risk of cardiovascular disease, rosuvastatin decreases the risk, especially among patients with increased inflammation. This is a proof-of-concept study to investigate whether the antiinflammatory effect of rosuvastatin is similar in depressive as in patients with cardiovascular disease.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Conditions

Depression

Interventions

rosuvastatinDRUG

10mg tablets, once daily in three months

PlaceboDRUG

tablet, once daily, three months

Eligibility

Sex: ALLMin age: 40 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Persisting self-reported depressive symptoms \> 5 weeks * Indications of aortic atherosclerosis on PET/CT Exclusion Criteria: * Clinical indication of statin use. * Contraindication of statins, or of PET/CT and MRI. * Established cardiovascular disease. * Bipolar disorder og comorbid psychosis.

Locations (1)

Akershus University Hospital

Lorenskog, Akershus, Norway

Outcomes

Primary Outcomes

Mean SUV of large arteries

Time frame: 3 months

Secondary Outcomes

Peripheral endothelial function (pulse wave amplitude)

Time frame: 3 months

Circulatory proinflammatory markers

Time frame: 3 months

Heart rate variability

Time frame: 3 months

Depressive symptoms

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.